Jefferies raised the firm’s price target on Praxis Precision (PRAX) to $65 from $61 and keeps a Buy rating on the shares after the company shared several epilepsy presentations at the IEC 2025 meeting. A “subtle new disclosure” is vormatrigine’s overall seizure-freedom rate of 14%, according to the analyst, who could envision “a meaningful +50-100% stock move” if its absolute efficacy is replicated in the subsequent placebo-controlled Phase 2/3 POWER1/2 datasets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success
- Praxis Precision price target raised to $115 from $105 at H.C. Wainwright
- Praxis Precision Medicines Reports Promising Study Results
- Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao
- Praxis Announces Positive Results from RADIANT Study